University of Minnesota. Driven to Discover.
Four research teams from India receive awards for point-of-care diagnostic tests, 3 of them focused on sepsis.
A review finds the biomarker cut mortality and antibiotic exposure in patients with acute respiratory infections.
Recommendations focus on public-private R&D funding, incentives, and other steps.
The fast, automated assay performs well against gold standard TB tests.
Point-of-care tests, shared decision making, and procalcitonin-guided therapy were singled out.
Funds will help combat resistance, launch a TB surveillance center.
The results suggest that clinical labs should consider using an additional test to validate results.
Two companies that have received funds—Spero Therapeutics and Entasis Therapeutics—say CARB-X support has been instrumental.
"If we can eradicate the empirical use of antibiotics . . . we can achieve a lot," Zowawi says.
The alliance aims to aid collaboration between the public and private sectors.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.